Results 301 to 310 of about 13,250,277 (360)
Synthetic high‐density lipoprotein (sHDL) nanodiscs are developed to co‐deliver liver‐X‐Receptor (LXR) agonists and Toll‐like receptor 9 (TLR‐9) agonist CpG for glioma treatment. By upregulation of ATP‐binding cassette transporter A1 (ABCA1), LXR agonists synergize with sHDL nanodiscs to deplete cholesterol and induce apoptosis of glioma cells.
Troy A. Halseth+12 more
wiley +1 more source
Challenges and opportunities for statistical power and biomarker identification arising from rhythmic variation in proteomics. [PDF]
Spick M+8 more
europepmc +1 more source
Lipoprotein receptors: A little grease for enveloped viruses to open the lock? [PDF]
Cosset FL, Denolly S.
europepmc +1 more source
Two‐dimensional graphene‐based nanomaterials are of significant interest in biomedical applications due to their unique physicochemical properties. Computational modeling provides useful insights into their structure and interactions with biological systems, aiding the nanoparticle design.
Alexa Kamboukos+2 more
wiley +1 more source
Potential causal evidence for an ApoB-independent and HDL-related risk profile associated with coronary artery disease. [PDF]
Ao L+5 more
europepmc +1 more source
In vivo, screening of DNA nanostructures yields a cube‐shaped structure (D‐Cb) as a protein corona‐assisted platform for brain delivery of oligonucleotide therapeutics. D‐Cb effectively delivers polo‐like kinase 1 (PLK‐1) antisense oligonucleotides (ASO) to treat glioblastoma in an orthotopic mouse model, demonstrating its potential as a carrier for ...
Kyoung‐Ran Kim+7 more
wiley +1 more source
Relevance of Lipoprotein Composition in Endothelial Dysfunction and the Development of Hypertension. [PDF]
Ramírez-Melo LM+7 more
europepmc +1 more source
This review explores the dual roles of exosomes in gastrointestinal (GI) cancers as diagnostic biomarkers and therapeutic agents. It highlights advancements in exosomal miRNAs, lncRNAs, circRNAs, and proteins for cancer detection and prognosis. The study also examines engineering strategies for exosome‐based drug delivery systems, their potential to ...
Mohit J. Mehta+7 more
wiley +1 more source
Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews. [PDF]
Xu Z, Yang S, Cui L.
europepmc +1 more source